Targeted radiation boosts standard care for lung cancer that has spread a little

NCT ID NCT02417662

Ongoing Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy improves survival for people with non-small cell lung cancer that has spread to only a few spots (oligometastatic). About 140 participants are randomly assigned to receive either standard therapy alone or standard therapy plus radiation to the primary tumor and metastases. The main goal is to see if the combination extends overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic ablative radiotherapy (SABR) and conventional radiotherapy
What this could lead to: If successful, adding SABR to standard therapy could improve survival and delay cancer progression for patients with limited metastatic lung cancer.
What could go wrong: This is a mid-stage trial with 140 participants, so results may not apply to all patients. Radiotherapy can cause side effects like fatigue or local tissue damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Addenbrooke's Hospital

Cambridge, United Kingdom
BEATSON

Glasgow, United Kingdom
Belfast City Hospital

Belfast, United Kingdom
Bristol Royal Infirmary

Bristol, United Kingdom
Christie Hospital

Manchester, United Kingdom
City Hospital

Nottingham, United Kingdom
Clatterbridge Cancer Centre

Metropolitan Borough of Wirral, United Kingdom
Freeman Hospital

Newcastle, United Kingdom
Guy's and St Thomas's Hospital

London, United Kingdom
Leicester Royal Infirmary

Leicester, United Kingdom
Queen Elizabeth Hospital

Birmingham, United Kingdom
Royal Surrey County Hospital

Guildford, United Kingdom
Southampton General Hospital

Southampton, United Kingdom
St Bart's Hospital

London, United Kingdom
St James's University Hospital

Leeds, United Kingdom
The James Cook University Hospital

Middlesbrough, United Kingdom
The Royal Marsden Hospital

London, United Kingdom
UCLH

London, England, United Kingdom
Weston Park Hospital

Sheffield, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.